QPPV.COM KNOWLEDGE ASSESSMENT

Faricimab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Faricimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A retinal tear occurs shortly after an injection, with documentation of difficult needle placement. Which interpretation is most consistent with the article?

The event should initially be considered a possible procedure-related complication The event proves Ang-2 inhibition caused retinal degeneration The event should be classified only as lack of efficacy The event is necessarily an immune-mediated reaction

Question 2 of 10 Why should spontaneous-report counts not be interpreted directly as adverse-event incidence when comparing products?

Spontaneous reports contain no clinical information Reporting counts are influenced by exposure, patient mix, reporting intensity, launch timing and diagnostic awareness Incidence can be calculated from counts without a denominator All products have identical market exposure

Question 3 of 10 Why is laterality a core pharmacovigilance variable for faricimab?

It determines whether the antibody binds VEGF-A or Ang-2 It helps identify the exposed eye and supports attribution when bilateral treatment or different fellow-eye therapies are involved It replaces the need to record the injection date It is relevant only for systemic adverse events

Question 4 of 10 A patient develops sudden visual loss after intravitreal faricimab. Which initial PV approach is most appropriate?

Code the event as drug-induced visual loss without further diagnostic clarification Assume it is endophthalmitis because it followed an injection Reconstruct the treated eye, injection timing and objective findings to distinguish competing causes Exclude the event because visual loss is expected in retinal disease

Question 5 of 10 Why should faricimab generally be assessed as one biological product rather than as two independent medicines?

The two targets are present only in systemic tissues Both binding specificities are incorporated into the same engineered molecule The product contains two separately administered injections The Ang-2 component is pharmacologically inactive

Question 6 of 10 Which record would provide the strongest minimum foundation for reconstructing an eye-specific faricimab exposure?

Product identity, batch, treated eye, injection date and information on fellow-eye treatment Only the patient's diagnosis and country Only the date of the first-ever retinal examination Only the reported symptom and its seriousness

Question 7 of 10 Which feature most strongly supports a distinct retinal vasculitis case series rather than pooling all cases under uveitis?

Retinal vasculitis has an anatomically and clinically specific vascular inflammatory phenotype Uveitis terms are never valid for ophthalmic cases Retinal vasculitis is always infectious All cases of uveitis have identical causality and urgency

Question 8 of 10 How should a myocardial infarction occurring after intravitreal faricimab generally be assessed?

Temporal association alone is sufficient to establish causality It should be ignored because ocular administration prevents any systemic exposure The event should be assessed with its phenotype, vascular risk factors, injection history and competing causes It should automatically be attributed to retinal vascular disease

Question 9 of 10 Which periodic benefit-risk conclusion is most consistent with the article?

Longer treatment intervals are beneficial regardless of recurrence or visual deterioration Benefit-risk review should consider visual and anatomical benefit, serious ocular risks, treatment burden, systemic observations, immunogenicity and administration problems Only systemic vascular events are relevant because ocular events are expected A reduction in injection frequency eliminates the need for ophthalmic monitoring

Question 10 of 10 A case report describes anterior chamber cells and vitritis after injection but does not mention infection. Which follow-up principle is most appropriate?

Automatically classify the event as infectious endophthalmitis Automatically classify it as retinal vasculitis Obtain ophthalmic findings and microbiological information where relevant before distinguishing sterile inflammation from infection Discard the report because inflammatory findings are not reportable

Faricimab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings